SCHEMBL6168062

SCHEMBL6168062

CC(=O)N1CCc2ccc(S(=O)(=O)N3CCc4ccccc43)cc2CC1

nearest known ligand 0.72

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.72
SMN1; SMN2 Q16637 2/20 0.72
TSHR P16473 1/20 0.60
PDE4A P27815 1/20 0.58
PDE4B Q07343 1/20 0.58
PDE4C Q08493 1/20 0.58
PDE4D Q08499 1/20 0.58
AKR1C3 P42330 1/20 0.58
AKR1C1 Q04828 1/20 0.58
LMNA P02545 2/20 0.57
MEN1 O00255 5/20 0.56
KMT2A Q03164 5/20 0.56
PKM P14618 2/20 0.56
USP2 O75604 1/20 0.54
STAT3 P40763 1/20 0.54
HTT P42858 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6330427 0.93 ALDH1A1 (0.69) ALDH1A1SMN1; SMN2TSHRPDE4APDE4B
SCHEMBL6167735 0.85 ALDH1A1 (0.53) ALDH1A1SMN1; SMN2TSHRLMNAPKM
SCHEMBL13841817 0.84 KMT2A (0.64) ALDH1A1SMN1; SMN2TSHRPDE4APDE4B
SCHEMBL6167372 0.81 KMT2A (0.60) ALDH1A1SMN1; SMN2TSHRPDE4APDE4B
SCHEMBL4035842 0.77 PNMT (0.49) ALDH1A1SMN1; SMN2LMNAMEN1KMT2A
SCHEMBL15682658 0.77 KMT2A (0.64) ALDH1A1SMN1; SMN2TSHRPDE4APDE4B
SCHEMBL6331056 0.77 KMT2A (0.57) ALDH1A1SMN1; SMN2TSHRPDE4APDE4B
SCHEMBL4040738 0.76 NOTUM (0.47) ALDH1A1SMN1; SMN2LMNAMEN1KMT2A
SCHEMBL6168219 0.75 HTR6 (0.54) ALDH1A1SMN1; SMN2TSHRLMNAMEN1
SCHEMBL4765964 0.75 HTR2C (0.64) ALDH1A1TSHRLMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1392316-B1 BENZO[D]AZEPINE DERIVATIVES AS 5-HT6 RECEPTOR ANTAGONISTS. SMITHKLINE BEECHAM PLC (GB) 2005-04-20 EP disclosed
US-20040192671-A1 Benzo[d]azepine derivatives as 5-ht6 receptor anatagonists SMITHKLINE BEECHAM P.L.C. (GB) 2004-09-30 US disclosed
EP-1392316-A1 BENZO[D]AZEPINE DERIVATIVES AS 5-HT6 RECEPTOR ANTAGONISTS. SMITHKLINE BEECHAM PLC (GB) 2004-03-03 EP disclosed
WO-2002089811-A1 BENZO[D]AZEPINE DERIVATIVES AS 5-HT6 RECEPTOR ANTAGONISTS. SMITHKLINE BEECHAM P.L.C. (GB) 2002-11-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192671-A1 Benzo[d]azepine derivatives as 5-ht6 receptor anatagonists HTR6, HTR5A, HTR1A ALDH1A1 1942/4885SMN1; SMN2 2084/4885TSHR 319/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.